Literature DB >> 26712092

Risk factors for Kaposi's sarcoma in human immunodeficiency virus patients after initiation of antiretroviral therapy: A nested case-control study in Kenya.

Rodgers Lupia1, Peter B Wabuyia2, Peter Otiato2, Chi-Tai Fang3, Feng-Jen Tsai4.   

Abstract

BACKGROUND/
PURPOSE: This study aimed to evaluate the association between highly active antiretroviral therapy (HAART) adherence and development of Kaposi's sarcoma (KS) in human immunodeficiency virus (HIV)/AIDS patients.
METHODS: We conducted a retrospective nested case-control study of 165 participants (33 cases and 132 controls) receiving HAART care at Maseno Hospital, Kenya, from January 2005 to October 2013. Cases were HIV-positive adults with KS, who were matched with controls in a ratio of 1:4 based on age (±5 years of each case), sex, and KS diagnosis date. Perfect adherence to HAART was assessed on every clinic visit by patients' self-reporting and pill counts. Chi-square tests were performed to compare socioeconomic and clinical statuses between cases and controls. A conditional logistic regression was used to assess the effects of perfect adherence to HAART, the latest CD4 count, education level, distance to health-care facility, initial World Health Organization stage, and number of regular sexual partners on the development of KS.
RESULTS: Only 63.6% participants reported perfect adherence, and the control group had a significantly higher percentage of perfect adherence (75.0%) than did cases (18.2%). After adjustment for potential imbalances in the baseline and clinical characteristics, patients with imperfect HAART adherence had 20-times greater risk of developing KS than patients with perfect HAART adherence [hazard ratios: 21.0, 95% confidence interval: 4.2-105.1]. Patients with low latest CD4 count (≤350 cells/mm3) had a seven-times greater risk of developing KS than did their counterparts (HRs: 7.1, 95% CI: 1.4-36.2).
CONCLUSION: Imperfect HAART adherence and low latest CD4 count are significantly associated with KS development.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Kaposi's sarcoma; Kenya; Maseno; antiretroviral therapy; highly active antiretroviral therapy; human immunodeficiency virus/AIDS treatment

Mesh:

Substances:

Year:  2015        PMID: 26712092     DOI: 10.1016/j.jmii.2015.10.009

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  8 in total

Review 1.  The role of infections in the causation of cancer in Kenya.

Authors:  Vivian C Tuei; Geoffrey K Maiyoh; Fidelis T Ndombera
Journal:  Cancer Causes Control       Date:  2022-09-10       Impact factor: 2.532

2.  Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.

Authors: 
Journal:  Clin Infect Dis       Date:  2016-08-17       Impact factor: 9.079

3.  Antiretroviral Therapy for HIV-Associated Cutaneous Kaposi's Sarcoma: Clinical, HIV-Related, and Sociodemographic Predictors of Outcome.

Authors:  Owen Ngalamika; Sody Munsaka; Salum J Lidenge; John T West; Charles Wood
Journal:  AIDS Res Hum Retroviruses       Date:  2021-02-02       Impact factor: 2.205

4.  Kaposi's sarcoma in persons living with HIV/AIDS: a case series in a tertiary referral hospital.

Authors:  Carla Andréa Avelar Pires; Marcos Antonio Neves Noronha; Julius Caesar Mendes Soares Monteiro; Albert Luiz Costa da Costa; José Maria de Castro Abreu Júnior
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

5.  Case report: dual primary AIDS-defining cancers in an HIV-infected patient receiving antiretroviral therapy: Burkitt's lymphoma and Kaposi's sarcoma.

Authors:  Seong Eun Kim; Younggon Jung; Tae Hoon Oh; Uh Jin Kim; Seung-Ji Kang; Hee-Chang Jang; Kyung-Hwa Park; Kyung-Hwa Lee; Sook In Jung
Journal:  BMC Cancer       Date:  2018-11-08       Impact factor: 4.430

6.  Three year survival among patients with aids-related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital, Kenya.

Authors:  Naftali Busakhala; Gabriel Kigen; Paul Waako; R Matthew Strother; Fredrick Chite; Patrick Loehrer
Journal:  Infect Agent Cancer       Date:  2019-09-10       Impact factor: 2.965

7.  Epidemiology of Kaposi's sarcoma in Zambia, 2007 - 2014.

Authors:  Maybin Kalubula; Heqing Shen; Mpundu Makasa
Journal:  Malawi Med J       Date:  2020-06       Impact factor: 0.875

8.  Reversible rituximab-induced rectal Kaposi's sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma.

Authors:  Emilien Billon; Anne-Marie Stoppa; Lena Mescam; Massimo Bocci; Audrey Monneur; Delphine Perrot; François Bertucci
Journal:  Clin Sarcoma Res       Date:  2018-06-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.